Compare Stocks

→ Move Your Money Before May 22 (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZRX AzurRx BioPharma	$2.74 +0.4%	$4.04	$3.36 ▼ $26.30	$25.55M	1.51	628,703 shs	44,714 shs
CLSN Imunon		$2.22	$1.80 ▼ $15.75	$13.91M	2.27	150,471 shs	711 shs
EVOK Evoke Pharma	$0.46 +4.6%	$0.59	$0.42 ▼ $2.40	$3.88M	0.22	53,219 shs	8,742 shs
QBIO Q BioMed	$0.00	$0.00	$0.00 ▼ $0.02	$29K	1.72	538 shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZRX AzurRx BioPharma	-3.21%	+6.34%	-23.93%	-38.99%	+5.96%
CLSN Imunon	0.00%	0.00%	0.00%	0.00%	0.00%
EVOK Evoke Pharma	-2.57%	-8.94%	-27.90%	-33.44%	-76.93%
QBIO Q BioMed	0.00%	0.00%	-33.33%	-75.00%	-98.55%

Move Your Money Before May 1 (Ad)

Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens?

Click here to get the full story before May 1.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLSN Imunon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A
CLSN Imunon	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
CLSN Imunon	$500K	0.00	N/A	N/A	$9.66 per share	0.00
EVOK Evoke Pharma	$5.18M	0.75	N/A	N/A	($0.77) per share	-0.59
QBIO Q BioMed	$280K	0.10	N/A	N/A	($0.11) per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
CLSN Imunon	-$20.77M	N/A	0.00	N/A	N/A	-5,229.80%	-50.18%	-36.94%	N/A
EVOK Evoke Pharma	-$7.79M	-$2.33	N/A	∞	N/A	-150.43%	-517.99%	-91.83%	5/20/2024 (Estimated)
QBIO Q BioMed	-$2.05M	-$0.03	N/A	∞	N/A	N/A	N/A	N/A	5/26/2024 (Estimated)

Latest AZRX, EVOK, CLSN, and QBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	EVOK Evoke Pharma	N/A	-$0.59	-$0.59	-$0.59	N/A	$1.68 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
CLSN Imunon	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZRX AzurRx BioPharma	N/A	1.33	1.33
CLSN Imunon	0.13	6.52	6.52
EVOK Evoke Pharma	N/A	2.25	2.09
QBIO Q BioMed	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
AZRX AzurRx BioPharma	6.27%
CLSN Imunon	12.97%
EVOK Evoke Pharma	N/A
QBIO Q BioMed	N/A

Insider Ownership

Company	Insider Ownership
AZRX AzurRx BioPharma	7.30%
CLSN Imunon	4.66%
EVOK Evoke Pharma	11.78%
QBIO Q BioMed	28.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
CLSN Imunon	27	7.10 million	6.77 million	Optionable
EVOK Evoke Pharma	4	8.48 million	7.48 million	Not Optionable
QBIO Q BioMed	3	145.10 million	104.18 million	Not Optionable

AZRX, EVOK, CLSN, and QBIO Headlines

Source	Headline
	E&Q Master Cordless Gutta Percha Obturator from Meta BioMed news-medical.net - March 24 at 4:19 AM
	Clearside Biomedical Q4 2023 Earnings Preview msn.com - March 11 at 7:34 PM
	Q BioMed Stock (OTC:QBIO) Dividends: History, Yield and Dates benzinga.com - February 24 at 3:23 AM
	Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates msn.com - February 13 at 1:26 PM
	Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth msn.com - January 28 at 11:09 PM
	Q BioMed Inc QBIO morningstar.com - November 16 at 1:23 PM
	Biomedical Sciences PhD Program uwyo.edu - November 13 at 2:32 PM
	Q&A: How generative AI could help accelerate biomedical research phys.org - November 6 at 8:46 AM
	QBIO Q BioMed Inc. seekingalpha.com - August 18 at 4:51 AM
	Q BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in Europe pharmabiz.com - April 17 at 9:36 AM
	Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value proactiveinvestors.com - April 14 at 10:53 AM
	Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe finance.yahoo.com - April 14 at 10:53 AM
	Q BioMed Stock (OTC:QBIO), Quotes and News Summary benzinga.com - March 3 at 4:23 PM
	Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B proactiveinvestors.com - February 10 at 3:27 PM
	Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office finance.yahoo.com - February 10 at 8:27 AM
	Short Volatility Alert: Q Biomed Inc benzinga.com - January 12 at 2:36 PM
	Q BioMed Inc. (QBIO) finance.yahoo.com - January 1 at 5:15 PM
	Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research proactiveinvestors.com - November 14 at 2:22 PM
	Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. finance.yahoo.com - November 14 at 9:20 AM
	Q BIOMED PROVIDES SHAREHOLDER UPDATE prnewswire.com - October 11 at 8:38 AM
	Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment proactiveinvestors.com - September 27 at 1:02 PM
	Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER finance.yahoo.com - September 27 at 1:02 PM
	Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc. finance.yahoo.com - August 25 at 10:16 AM
	What to Expect at BIOMEDevice Boston mddionline.com - August 10 at 3:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AzurRx BioPharma

NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Imunon

NASDAQ:CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Evoke Pharma

NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Q BioMed

OTCMKTS:QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial